NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
TCMD
Tactile Systems Technology, Inc.
TCMD has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TCMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
TCMD's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over TCMD in the historical PE scenario, which offers more potential upside but is not a forecast.
TCMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $13.15 | -51% |
| Forward | 21x | $26.82 | — |
| Current | 26x | $26.82 | — |
| Fair | 27x | $27.39 | +2.1% |
| Expensive | 89x | $91.05 | +240% |
Historical ranges are pointers, not guarantees.
TCMD's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TCMD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
TCMD has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over TCMD on earnings, with more consistent year-over-year improvement.
TCMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.25 | +23% |
| Q3 2026 | $1.02 | +32% |
| Q2 2026 | $1.07 | +73% |
| Q1 2026 | $0.87 | +32% |
| Q4 2025 | $0.82 | +17% |
| Q3 2025 | $0.77 | +13% |
| Q2 2025 | $0.62 | -56% |
| Q1 2025 | $0.66 | -46% |
| Q4 2024 | $0.70 | -43% |
TCMD's earnings per share have fallen from their peak: $1.02 over the past year, against $1.41 in mid-2024.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over TCMD on profitability, with a higher operating margin.
TCMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $91.9M | +7.1% |
| Q2 2026 | $85.7M | +8.6% |
| Q1 2026 | $75.3M | +23% |
| Q4 2025 | $103.6M | +21% |
| Q3 2025 | $85.8M | +17% |
| Q2 2025 | $78.9M | +7.8% |
| Q1 2025 | $61.3M | +0.3% |
| Q4 2024 | $85.6M | +10% |
TCMD's revenue has grown year over year for 22 quarters in a row: $92M last quarter, up 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | -2.3 points |
| Q2 2026 | 8% | +2.8 points |
| Q1 2026 | -2% | +5.4 points |
| Q4 2025 | 18% | +3.5 points |
| Q3 2025 | 13% | +3.5 points |
| Q2 2025 | 5.2% | -2.8 points |
| Q1 2025 | -7.4% | -2.6 points |
| Q4 2024 | 15% | -0.6 points |
TCMD's operating margin was 10% last quarter, down 2.3 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over TCMD on cash flow, with more consistent year-over-year improvement.
TCMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.4M | +24% |
| Q2 2026 | $2M | -86% |
| Q1 2026 | -$1.2M | -3153% |
| Q4 2025 | $16.8M | +5.8% |
| Q3 2025 | $9.2M | -0.9% |
| Q2 2025 | $14.4M | +14% |
| Q1 2025 | $38K | -91% |
| Q4 2024 | $15.9M | -9% |
TCMD generated $29M in free cash flow over the past year, down 27% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over TCMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
TCMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -13K shares |
| 1 year | +2.4% | +533K shares |
| 3 years | -3.4% | -803K shares |
| 5 years | +16% | +3.3M shares |
| Available history | +17% | +3.4M shares |
TCMD has 23M diluted shares, up 2.4% from a year ago, despite $13M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6.2M |
| Q2 2026 | $5.3M |
| Q1 2026 | $1.1M |
| Q4 2025 | $1,000 |
| Q3 2025 | — |
| Q2 2025 | $16.5M |
| Q1 2025 | $10M |
TCMD spent $13M buying back its own shares over the past year.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
TCMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.9x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q4 2025 | -2.3x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.4x | Net Cash |
TCMD has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TCMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.2 | Neutral |
| Stochastic | 45.3 | Neutral |
TCMD's weekly RSI is 57 (neutral) and its Stochastic is 45 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over TCMD on valuation relative to its sector.
TCMD PE vs Healthcare Sector
| Metric | TCMD | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 1.7% above |
| PE % | 49 | 29 | 20 pts above |
TCMD is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
TCMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.7 | 13% above |
| 20 week MA | $25.1 | 6.9% above |
| 50 week MA | $26.2 | 2.3% above |
| 100 week MA | $20.3 | 32% above |
| 200 week MA | $18.0 | 49% above |
TCMD has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
TCMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $68.3 | $41.6 | -39% |
| 2021 | $41.6 | $20.2 | -51% |
| 2022 | $20.2 | $11.7 | -42% |
| 2023 | $11.7 | $14.3 | +22% |
| 2024 | $14.3 | $17.3 | +21% |
| 2025 | $17.3 | $29.7 | +72% |
| 2026 YTD | $29.7 | $26.8 | -9.6% |
TCMD has the edge over NVO on returns for 2026, with the stronger performance.